{
  "id": 2896168,
  "title": "Pfizer’s Turnaround is Gaining Traction, but Can New Products Offset its Patent Cliff?",
  "url": "https://urgent.news/2026/08/23/pfizers-turnaround-is-gaining-traction-but-can-new-products-offset",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-23T23:13:13.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/healthcare/articles/pfizer-turnaround-gaining-traction-products-231313770.html"
  },
  "original_language": "en",
  "account": "Pfizer Inc. (NYSE: PFE) has begun showing signs of steadier growth as its pandemic-related business begins to decline. In fiscal Q2 2026, the company reported a 1% year-over-year increase in operational revenue to $15.0 billion. Excluding sales of Comirnaty and Paxlovid, revenue grew 5% operationally. Management raised its midpoint guidance for the full year. However, Pfizer's recovery still depends on whether growth from newer products and cost reductions can offset upcoming patent expirations for several established medicines. A positive sign for investors is Pfizer's reduced reliance on COVID-related sales, as non-COVID products drove growth. Non-COVID medicines generated $3.2 billion in quarterly revenue, with an 18% operational increase. Cost cuts have also been implemented, with Pfizer aiming for $5.7 billion in net savings by the end of 2026, and up to $6.7 billion through 2029. These savings may help maintain margins and invest in areas like oncology and obesity. However, Pfizer's recovery is incomplete, as significant revenue pressure from patent expirations between 2026 and 2030 remains. Products like Eliquis, Ibrance, and Xtandi are facing competition from generics and biosimilars, and investors still lack confidence that the company's newer portfolio can replace the revenue at risk. Hedge fund interest in Pfizer remains stable but modestly positive, indicating cautious optimism. While Pfizer's turnaround efforts are promising, particularly with the growth of products like Padcev and Vyndaqel, the long-term success of the company will depend on the ability of its newer medicines to generate sufficient revenue to replace the losses expected from patent expirations.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}